Efficacy of pergolide for the management of equine pituitary pars intermedia dysfunction: A systematic review

• Published in: The veterinary journal (1997) 2020-12, Vol.266, p.105562-105562, Article 105562
• Main Authors: Tatum, R.C., McGowan, C.M., Ireland, J.L.
• Format: Article
• Language: English
• Subjects: Adrenocorticotropic Hormone - blood; Animals; Cushing's disease; Dopamine agonist; Horse; Horse Diseases - drug therapy; Horses; Pergolide - administration & dosage; Pergolide - therapeutic use; Pituitary Diseases - drug therapy; Pituitary Diseases - veterinary; Pituitary Gland, Intermediate - drug effects; PPID; Treatment; Treatment Outcome
• ISSN: 1090-0233; 1532-2971
• DOI: 10.1016/j.tvjl.2020.105562

•Clinical trials of pergolide treatment for pituitary pars intermedia dysfunction (PPID) are lacking.•Clinical improvement reported in 40–100% of pergolide-treated PPID cases.•Reduced adrenocorticotrophic hormone (ACTH) in 44–74% of pergolide-treated cases.•Return of ACTH to reference intervals reported in 28–74% of pergolide-treated cases. Pergolide, a dopamine agonist, is commonly administered to manage pituitary pars intermedia dysfunction (PPID), a progressive neurodegenerative disease prevalent in aged horses. However, available evidence regarding pergolide's efficacy in improving clinical and endocrine parameters is limited. The aim of this systematic review was to assess published literature and evaluate evidence regarding whether pergolide treatment results in improvement of clinical signs and/or adrenocorticotrophic hormone (ACTH) concentration compared to no treatment or other unlicensed treatments. Systematic searches of electronic databases were undertaken in April 2019, repeated in August and October 2019, and updated in July 2020. English language publications published prior to these dates were included. Screening, data extraction and quality assessment of publications was undertaken individually by the authors using predefined criteria and subsequently cross-checked. Modified critically appraised topic data collection forms were used to extract data. Due to marked between-study variations, meta-analysis was not undertaken. After removal of duplicate records; 612 publications were identified, of which 129 abstracts were screened for eligibility and 28 publications met criteria for inclusion in the review. Most studies were descriptive case series, cohort studies or non-randomised, uncontrolled field trials. Despite marked variation in study populations, case selection, diagnostic protocols, pergolide dose, follow-up period and outcome measures, in the vast majority of the included studies, pergolide was reported to provide overall clinical improvement in >75% of cases. However, reported improvements in individual clinical signs varied widely. A reduction in plasma ACTH concentrations was reported in 44–74% of cases, while normalisation to within reported reference intervals occurred in 28–74% of cases.